Lilly Agrees With Stipple Bio on Cancer Research Deal That Could Reach $5.9 Billion
Key Facts
Stipple Bio announced on November 16, 2026, that it had entered a multi-target, multi-modality research collaboration and licensing agreement with Eli Lilly in oncology. Under the agreement, Stipple could receive payments totaling up to $5.9 billion upon reaching milestones tied to research, product development and commercialization. That figure is a ceiling on payments contingent on achievement, not an amount Lilly is guaranteed to pay when the agreement is signed. The terms also include an upfront payment and an investment in Stipple, as well as potential rights to tiered royalties if Lilly commercializes treatments resulting from the collaboration. Lilly receives exclusive worldwide rights to develop and commercialize products arising from the agreement.
Stipple will use its Pointillist platform to discover binders targeting epitopes on the surface of tumor cells, while Lilly will combine those binders with its own oncology technologies. The work aims to develop compounds across multiple therapeutic modalities, according to the company announcement. Stipple says identifying tumor-specific binders could enable selective targeting of tumor cells. The company believes this approach could increase efficacy and reduce off-tumor toxicity caused by targeting cells. Stipple presents the technology as a basis for developing precision therapies, but the announcement describes the platform's potential and does not establish clinical results or a realized reduction in side effects.
The platform is based on identifying tumor-associated surface epitopes and creating antibody binders that target them, according to Stipple's description of its technology. The binders are intended to support precision cancer treatments by increasing therapeutic potency and reducing off-tumor effects, the company says. The agreement gives Lilly broad scope to develop potential products based on targets and binders discovered through the work. The consideration Stipple receives depends, to a large extent, on research and development progress followed by commercial milestones. Reaching the announced maximum therefore remains contingent on future milestones, alongside the upfront payment, investment and potential tiered royalties.
In a separate development to watch, Stipple plans to begin a Phase 1 clinical trial of its STP-100 candidate in early 2027. The candidate targets solid tumors, including pancreatic cancer, according to the company announcement. Stipple's pipeline page lists the program under solid tumors, including pancreatic ductal adenocarcinoma, while classifying the Lilly collaboration as being in the discovery stage. The announced trial timing applies to STP-100; the announcement does not specify a similar timeline for programs arising from the Lilly collaboration. That makes the planned early 2027 trial the nearest development milestone cited in the announcement.
The partnership comes as Lilly reported revenue of $23.0 billion in the second quarter of 2026, up 48% year over year. The company raised its full-year revenue forecast to a range of $85.0 billion to $87.0 billion. Chief Executive David Ricks said new assets were entering the company's pipeline through business development, alongside added manufacturing capacity. In its results for the same quarter, Lilly reported $3.03 billion in acquired in-process research and development costs, compared with $0.14 billion in the second quarter of 2025. The figures provide context for the company's expansion of its research pipeline through deals, while the Stipple agreement ties most of its payments to specific milestones.
Lilly shares, traded under the ticker LLY, closed at $1,431.67 on November 16, 2026, according to EL7 data. The closing price was from the session on the day the agreement was announced and does not by itself show the deal's effect on the stock. The agreement gives Lilly exclusive worldwide rights to potential products, while Stipple receives payments tied to research, development and commercialization milestones. The next timeline milestone cited in the announcement is the planned Phase 1 trial of STP-100 in early 2027. The announcement did not specify when any milestone payments might be achieved or when treatments from the collaboration might be launched.